2. Search Result
Search Result
Results for "

Cryptococcal meningitis

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-147110
    APX2039

    		Fungal Infection Inflammation/Immunology
    APX2039 is an orally active and potent inhibitor of the fungal Gwt1 enzyme. APX2039 has extremely potent anticryptococcal activity against C. neoformans and C. gattii. APX2039 blocks the localization of GPI (glycosylphosphatidyl inositol)-anchored cell wall mannoproteins. APX2039 can be used for Cryptococcal meningitis (CM) research .
    APX2039
  • HY-109040
    Quilseconazole

    VT-1129

    		 Fungal Cytochrome P450 Infection Inflammation/Immunology
    Quilseconazole (VT-1129) is an orally active, highly selective fungal cytochrome P450 enzyme Cyp51 inhibitor that can cross the blood-brain barrier. Quilseconazole prevents the synthesis of ergosterol, an important component of the fungal cell membrane, by inhibiting Cyp51. Quilseconazole has minimal effects on human CYP enzymes. Quilseconazole has antifungal activity and can be used in the study of cryptococcal meningitis and other diseases .
    Quilseconazole
  • HY-176483
    Antifungal agent 133

    		Fungal Infection
    Antifungal agent 133 (compound D2) is an orally active antifungal agent with a MIC80 of 0.13 ug/mL against C.neoformans H99. Antifungal agent 133 can be used for study of cryptococcal meningitis .
    Antifungal agent 133
  • HY-144632
    Antifungal agent 22

    		Fungal Infection
    Antifungal agent 22 (compound D16) is a potential and orally active antifungal agent for CM (cryptococcal meningitis), with an IC50 of 0.5 μg/mL. Antifungal agent 22 can penetrate the blood-brain barrier and kill the C. neoformans H99 cells by destroying the integrity of fungal cell membranes. Antifungal agent 22 shows selective anti-Cryptococcus activity with good metabolic stability and low cytotoxicity .
    Antifungal agent 22
  • HY-144643
    CYP51/HDAC-IN-1

    		Fungal HDAC Cytochrome P450 Inflammation/Immunology
    CYP51/HDAC-IN-1 is a potent, orally active CYP51/HDAC dual inhibitor. CYP51/HDAC-IN-1 inhibits important virulence factors and down-regulated resistance-associated genes. CYP51/HDAC-IN-1 exhibits potent therapeutic effects for both tropical candidiasis and cryptococcal meningitis .
    CYP51/HDAC-IN-1
  • HY-109040R
    Quilseconazole (Standard)

    		Fungal Cytochrome P450 Infection Neurological Disease Inflammation/Immunology
    Quilseconazole (Standard) is the analytical standard of Quilseconazole (HY-109040). This product is intended for research and analytical applications. Quilseconazole (VT-1129) is an orally active, highly selective fungal cytochrome P450 enzyme Cyp51 inhibitor that can cross the blood-brain barrier. Quilseconazole prevents the synthesis of ergosterol, an important component of the fungal cell membrane, by inhibiting Cyp51. Quilseconazole has minimal effects on human CYP enzymes. Quilseconazole has antifungal activity and can be used in the study of cryptococcal meningitis and other diseases .
    Quilseconazole (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: